Hierarchical classification of HU-criteria for fibrous plaques.

<p>Hierarchical classification of HU-criteria for fibrous plaques.</p

Search strategy and result.

<p>Search strategy and result.</p

Hierarchical classification of HU-criteria for lipid-rich plaques.

<p>Hierarchical classification of HU-criteria for lipid-rich plaques.</p

HU criteria for lipid-rich and fibrous plaques versus the reported lumen contrast-enhancement.

<p>HU criteria for lipid-rich and fibrous plaques versus the reported lumen contrast-enhancement.</p

Additional file 1: Table S1. of Airway wall thickness on HRCT scans decreases with age and increases with smoking

Cumulative APF at the different airway diameters per lung lobe. Table S2. Airway wall thickness per lobe. Table S3. Airway wall area per lobe. Table S4. Airway wall thickness according to smoking status. Table S5. Airway wall area according to smoking status. Table S6: Associations between airway wall thickness and age, gender and smoking status. Table S7. Associations between airway wall area and age, gender and smoking status. Table S8. Association between pulmonary function parameters and airway wall thickness, independent of age, gender, smoking status and height. Table S9. Association between pulmonary function parameters and airway wall area, independent of age, gender, smoking status and height. (DOCX 51 kb

CVD event HRs and 95% CIs in current smokers as compared with former smokers.

*<p>Adjusted for age (continuous) and pack years (continuous).</p>†<p>Adjusted for age (continuous), pack years (continuous), Left Anterior Descending.</p>‡<p>Coronary Artery Calcifications(3 categories),</p>§<p>Descending Aorta Calcifications (3 categories).</p

Baseline characteristics of cardiovascular disease cases and the subcohort.

<p>Values of continuous variables are expressed as median (range) because of non-normal distribution. Categorical variables are expressed as percentages.</p>*<p>LAD, Left Anterior Descending.</p

End diastolic and end systolic contours of the left ventricle.

<p>Effect of I/R in the MR16-1 and control IgG groups on cardiac function as measured by Cardiac Magnetic Resonance Imaging and visualized with mean and standard deviation; (A) Average case of the control IgG I/R group with end systolic and end diastolic contours, volumes and LVEF (LVESV 57 μl, LVEDV 85 μl, LVEF 32%); (B) Average case of the MR16-1 treatment I/R group with end systolic and end diastolic contours, volumes and LVEF (LVESV 60 μl, LVEDV 81 μl, LVEF 26%); (C) Average case of the IgG sham group with end systolic and end diastolic contours, volumes and LVEF (LVESV 32 μl, LVEDV 56 μl, LVEF 43%); (D) Average case of the MR16-1 sham group with end systolic and end diastolic contours, volumes and LVEF (LVESV 33 μl, LVEDV 60 μl, LVEF 44%).</p

Medication use of study groups.

<p>ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker.</p

Organ weights and histology 28 days after surgery.

<p>Organ weights and histology 28 days after surgery.</p